Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0273 | Levosimendan

Molecular Formula C14H12N6O
Molecular Weight 280.28
Structure
State solid
Protein binding 98% bound to plasma protein.
Half life Eliminination half-life is approximately 1 hour.
Absorption The bioavailability of oral levosimendan is 85 ± 6% in healthy volunteers and 84 ± 4% in patients.
Trade names Simdax

C

C01CX08 Levosimendan


[C01CX] Other cardiac stimulants


[C01C] CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES


[C01] CARDIAC THERAPY


[C] Cardiovascular system

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 41 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H302 (95.12%): Harmful if swallowed [Warning Acute toxicity, oral]


H312 (92.68%): Harmful in contact with skin [Warning Acute toxicity, dermal]


H332 (92.68%): Harmful if inhaled [Warning Acute toxicity, inhalation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P312, P322, P330, P363, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Cardiac failure acute

  • Cardiac failure chronic

    • ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile (-)-OR-1259 (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile
    (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile (R)-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide (R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide
    (R)-Simendan ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile 1-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}methanecarbohydrazonoyl cyanide
    141505-33-1 2-[[4-[(4R)-4-methyl-6-oxidanylidene-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
    741L087 A11874 A807767
    AB01562970_01 AB01562970_02 AC-1752
    ACT02710 AKOS015895214 AM84381
    API0003165 BCP07048 C6T4514L4E
    CAS-141505-33-1 CCG-213048 CHEBI:50567
    CHEMBL2051955 CS-2501 D04720
    DB00922 DS-8918 DSSTox_CID_26445
    DSSTox_GSID_46445 DSSTox_RID_81620 DTXSID9046445
    FT-0657758 HMS3264G03 HY-14286
    KS-00000IR8 KSC-210-010 KUC109648N
    LEVOSIMENDAN LS-120045 Levosimedan
    Levosimendan (USAN/INN) Levosimendan [INN] Levosimendan [USAN:INN]
    Levosimendan, >=98% (HPLC) MLS003899227 MLS006010741
    Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone Mesoxalonitrile (p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone NCGC00253641-01
    NCGC00263564-01 NCGC00263564-02 NSC-759644
    NSC759644 OR 1259 OR-1259
    OR1259 Pharmakon1600-01502356 Q162541
    SB17415 SCHEMBL83243 SMR002529692
    SR-01000931342 SR-01000931342-2 SW219172-1
    Simdax Simdax (TN) Tox21_112191
    Tox21_112191_1 Tox21_113768 UNII-349552KRHK component WHXMKTBCFHIYNQ-SECBINFHSA-N
    UNII-C6T4514L4E WHXMKTBCFHIYNQ-SECBINFHSA-N ZINC3915645
    levosimendanum s2446

    DrugBank Name Levosimendan
    DrugBank DB00922
    CAS Number 131741-08-7, 141505-33-1
    PubChem Compound 3033825
    KEGG Drug D04720
    PubChem.Substance 46507149
    ChEBI 50567
    PharmGKB PA164749138
    ChemSpider 2298414
    TTD DAP000797
    Wikipedia Levosimendan